| ID Source | ID |
|---|---|
| PubMed CID | 159643 |
| CHEBI ID | 156351 |
| SCHEMBL ID | 15943044 |
| MeSH ID | M0046172 |
| Synonym |
|---|
| gougerotin |
| nsc528943 |
| asteromycin |
| nsc-528943 |
| 6-(4-amino-2-oxo-3,4-dihydro-2h-pyrimidin-1-yl)-4,5-dihydroxy-3-[3-hydroxy-2-(2-methylamino-acetylamino)-propionylamino]-tetrahydro-pyran-2-carboxylic acid amide |
| 4,5-dihydroxy-3-[[3-hydroxy-2-[[2-(methylamino)acetyl]amino]propanoyl]amino]-6-(4-imino-2-oxo-pyrimidin-1-yl)tetrahydropyran-2-carboxamide |
| aspiculamycin |
| quingfengmycin |
| antibiotic 21544 |
| CHEBI:156351 |
| SCHEMBL15943044 |
| glucopyranuronamide, 1-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1,4-dideoxy-4-(d-2-(2-(methylamino)acetamido)hydracrylamido)-, .beta.-d- |
| 1-(4-deoxy-4-(sarcosyl-d-seryl)amino-.beta.-d-glucopyranuronamide)cytosine |
| AMNAZJFEONUVTD-UHFFFAOYSA-N |
Gougerotin is a peptidyl nucleoside antibiotic produced by Streptomyces graminearus.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Gougerotin is a peptidyl nucleoside antibiotic produced by Streptomyces graminearus . " | ( Combined gene cluster engineering and precursor feeding to improve gougerotin production in Streptomyces graminearus. Jiang, L; Li, L; Niu, G; Tan, H; Wei, J, 2013) | 2.07 |
| "Gougerotin is a peptidyl nucleoside antibiotic. " | ( GouR, a TetR family transcriptional regulator, coordinates the biosynthesis and export of gougerotin in Streptomyces graminearus. Niu, G; Tan, H; Tian, Y; Wei, J, 2014) | 2.07 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 20 (71.43) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 1 (3.57) | 29.6817 |
| 2010's | 6 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.82) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (6.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 28 (93.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||